Baxter International Inc. (BAX)
Is Now The Time To Buy Baxter Stock?
Baxter stock (NYSE: BAX), a healthcare company, has seen its stock decline by 14% over the past month. This drop followed a disappointing earnings report where the company also reduced its full-year guidance, partly due to Hurricane Helene impacting one of its manufacturing facilities.
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
Baxter International (BAX) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.68 per share a year ago.
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stay Ahead of the Game With Baxter (BAX) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
Medical Equipment Maker Baxter International Names New CEO
Baxter International on Monday named Andrew Hider, chief executive of Canadian automation solutions firm ATS Corp., its new CEO.
3 Top Goldman Sachs Dividend Stock Picks Have Up to 73% Upside Potential
After a volatile stretch, yields in the Treasury bond market have stabilized. Concerns about the volatility in the bond and stock markets are leading investors to top-quality dividend stocks.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
The 'Goldilocks' Case For Baxter International
Baxter International's stock has been challenging to own for the past decade, initially due to high valuations and later due to execution concerns and an ugly acquisition. During the pandemic, health care stocks, including Baxter, underperformed expectations, with BAX peaking in April 2020 before declining. But the divestiture of the kidney care business will help the balance sheet, and management is optimistic toward 2025 performance.
Baxter International Inc. (BAX) Q1 2025 Earnings Call Transcript
Baxter International Inc. (NYSE:BAX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President and Chief Investor Relations Officer Brent Shafer - Chairman and Interim Chief Executive Officer Heather Knight - Chief Operating Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi David Roman - Goldman Sachs Travis Steed - BofA Securities Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Larry Biegelsen - Wells Pito Chickering - Deutsche Bank Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
